Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Ginseng Study Suggests Improved Breast Cancer Survival Rate

This article was originally published in The Tan Sheet

  • News

Executive Summary

Regular ginseng users who were diagnosed with breast cancer were 30% more likely to survive the illness than women who never used the herb, according to a study slated for April 1 publication in the American Journal of Epidemiology

You may also be interested in...



NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients

NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients

NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS099239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By